Martine Latta-mahieu

Title: Martine Latta-Mahieu: Innovator in Neurodegenerative Treatments

Introduction

Martine Latta-Mahieu is a notable inventor based in Paris, France. He has made significant contributions to the field of neurodegenerative diseases through his innovative research and patenting efforts. His work focuses on developing RNA interference (RNAi) technologies aimed at treating conditions such as Parkinson's disease.

Latest Patents

Martine holds a patent for a "Variant RNAi against alpha-synuclein." This patent provides RNAi molecules designed to treat neurodegenerative synucleinopathies. The RNAi molecules specifically target the expression of alpha-synuclein (SNCA). Additionally, the patent includes expression constructs, vectors (such as rAAV), cells, viral particles, and pharmaceutical compositions that incorporate the RNAi. The methods and kits related to this RNAi are intended for treating various neurodegenerative conditions, including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies.

Career Highlights

Martine Latta-Mahieu is associated with Genzyme Corporation, a company known for its focus on biotechnology and pharmaceuticals. His work at Genzyme has allowed him to contribute to groundbreaking research in the treatment of neurodegenerative diseases.

Collaborations

Martine collaborates with esteemed colleagues, including Bradford Elmer and Brenda Richards, who bring diverse expertise to their projects. Their teamwork enhances the potential for innovative solutions in the field of neurodegenerative research.

Conclusion

Martine Latta-Mahieu's contributions to the field of neurodegenerative treatments through his patent and collaborative efforts highlight his role as a key innovator. His work continues to pave the way for advancements in medical science.